Kapruvia (Difelikefalin)

Difelikefalin acts as a selective agonist at peripheral kappa‑opioid receptors located on sensory nerves and immune cells. Activation of these receptors blocks the release of itch‑inducing mediators and dampens neuronal signaling that transmits itch sensations to the brain, while remaining largely outside the central nervous system.

The dosing regimen for Kapruvia is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. Specific dose amounts, infusion rates, and treatment intervals are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety data for difelikefalin in pregnant or lactating women are limited, and the product is not classified for use in these populations. Clinicians should weigh potential benefits against unknown risks and consider alternative therapies when treating pregnant or nursing patients.

To request Kapruvia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Kapruvia’s mechanism differs from traditional antihistamines or gabapentinoids because it targets peripheral kappa‑opioid receptors rather than histamine pathways or neuronal calcium channels. This selectivity can provide itch relief without the sedation commonly seen with gabapentin, and it avoids central opioid effects associated with non‑selective opioids.

Kapruvia should be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If the product must be transported, maintain the cold‑chain to preserve stability and efficacy.

Kapruvia is supplied as an injectable solution for intravenous use. It is typically administered as a slow infusion over a few minutes under clinical supervision. The exact infusion rate and duration are set by the treating physician according to the patient’s condition and response.

The most serious adverse reactions include anaphylactic or severe hypersensitivity responses, marked hypotension that can lead to syncope, and rare cases of respiratory depression. Patients should be monitored during and after infusion for any signs of these events, and emergency measures should be readily available.

Kapruvia is contraindicated in individuals with known hypersensitivity to difelikefalin or any component of the formulation. It should also be avoided in patients with severe uncontrolled hypotension or those who have experienced severe allergic reactions to similar kappa‑opioid agents.